Roche and Flare Therapeutics Launch $1.8B-Plus Cancer Collaboration Targeting Transcription Factors

Partnership Details:
Roche and Flare Therapeutics have announced a strategic discovery collaboration focusing on transcription factor targets in oncology, with a potential value of over $1.8 billion plus royalties235.

Financial Terms:
Flare Therapeutics will receive a $70 million upfront cash payment and is eligible for discovery, development, and commercial milestone payments35.

Collaboration Structure:
Flare will lead discovery and preclinical activities, while Roche will handle further development and commercialization. Flare retains the right to co-fund development for one target in exchange for increased U.S. royalties35.

Objective:
The partnership aims to discover novel small molecule drugs targeting transcription factors, which play a crucial role in various oncological diseases and have the potential to address high unmet medical needs135.

Expertise:
The collaboration combines Roche's leading expertise and global reach in oncology with Flare Therapeutics' deep knowledge in drug discovery for difficult-to-drug transcription factor targets5.

Sources:

1. https://endpts.com/roche-teams-with-flare-therapeutics-on-transcription-factors/

2. https://www.fiercebiotech.com

3. https://www.prnewswire.com/news-releases/flare-therapeutics-announces-strategic-discovery-collaboration-with-roche-to-address-previously-undrugged-transcription-factor-targets-in-oncology-302301901.html

5. https://www.stocktitan.net/news/RHHBY/flare-therapeutics-announces-strategic-discovery-collaboration-with-6j2qebga20ae.html